Viyash Scientific Share Price

Conference Call with Viyash Scientific Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 2 weeks 5 days ago

Pharmaceuticals company Viyash Scientific announced Q4FY26 & FY26 results Consolidated Financial Highlights Revenue from Operations: Consolidated revenue for Q4FY26 was Rs 9,199.60 million, up 7.17% QoQ from Rs 8,584.10 million and up 19.12% YoY from Rs 7,723.10 million. For the full year FY26, revenue was Rs 34,203.10 million, an increase of 13.75% YoY from Rs 30,068.40 million in FY25. Total Income: Consolidated total income for Q4FY26 reached Rs 9,358.80 million, a growth of 7.28% QoQ and 19.59% YoY. Annual total income for FY26 stood at Rs 34,638.60 million compared to Rs 30,397.30 million in FY25. Profit Before Tax (PBT): Consolidated PBT for Q4FY26 was Rs 1,252.40 million, up 71.40% QoQ from Rs 730.70 million and a significant turnaround from a loss of Rs 366.60 million in Q4FY25. For the full year FY26, PBT grew to Rs 3,490.20 million from Rs 131.80 million in FY25. Net Profit After Tax (PAT): Consolidated net profit for Q4FY26 was Rs 663.80 million, up 36.81% QoQ from Rs 485.20 million and a turnaround from a loss of Rs 321.80 million in Q4FY25. For the full year FY26, consolidated PAT reached Rs 2,246.50 million, marking a massive increase from Rs 157.70 million in FY25. Total Comprehensive Income: Consolidated total comprehensive income for FY26 was Rs 3,315.50 million compared to Rs 308.00 million in FY25. Earnings Per Share (EPS): Consolidated basic EPS for FY26 grew to Rs 4.09 from Rs 0.54 in FY25. Standalone Financial Highlights Revenue from Operations: The company reported revenue of Rs 3,724.90 million for Q4FY26, representing a growth of 9.03% QoQ from Rs 3,416.40 million in Q3FY26 and an increase of 8.18% YoY from Rs 3,443.20 million in Q4FY25. For the full year FY26, revenue stood at Rs 13,820.60 million, up 5.47% YoY compared to Rs 13,103.40 million in FY25. Total Income: Total income for Q4FY26 was Rs 3,922.40 million, up 9.58% QoQ from Rs 3,579.30 million and up 7.81% YoY from Rs 3,638.30 million. Annual total income for FY26 was Rs 14,483.20 million compared to Rs 13,825.50 million in FY25. Profit Before Tax (PBT): For Q4FY26, standalone PBT stood at Rs 487.50 million, a substantial increase compared to Rs 106.10 million in Q3FY26 and a turnaround from a loss of Rs 302.00 million in Q4FY25. Annual PBT for FY26 reached Rs 1,162.20 million, a growth of 136.36% YoY from Rs 491.70 million in FY25. Net Profit After Tax (PAT): The company recorded a net profit of Rs 358.10 million in Q4FY26, recovering from a marginal loss of Rs 0.80 million in Q3FY26 and a loss of Rs 193.70 million in Q4FY25. Annual PAT for FY26 was Rs 758.70 million, up 29.71% YoY from Rs 584.90 million in FY25. Total Comprehensive Income: Standalone total comprehensive income for FY26 was Rs 748.90 million compared to Rs 581.70 million in FY25. Earnings Per Share (EPS): Basic standalone EPS for FY26 improved to Rs 1.75 from Rs 1.36 in FY25. Business Highlights Segment Performance: The Board of Directors monitors the company's business activity as a single segment, namely Pharmaceuticals. Amalgamation: The company successfully completed a Composite Scheme of Amalgamation involving Sequent Research Limited and Viyash Life Sciences Private Limited, along with several other subsidiaries, with an appointed date of April 1, 2025. The scheme became effective on December 16, 2025. Grant of Stock Options: The Board approved the grant of 1,30,98,000 stock options to eligible employees under the "Viyash Scientific Limited Employee Stock Option Scheme 2026." Dividend: The Board has not recommended any dividend for FY26 to conserve resources. Equity and Warrants: Pursuant to the amalgamation scheme, the company allotted 18,19,21,827 fully paid-up equity shares and 2,03,41,257 warrants. Assets Held for Sale: During FY26, the company recorded a profit of Rs 42.60 million on the sale of land, building, and other assets at its manufacturing facility in Visakhapatnam. Result PDF

• Trendlyne
• 2 weeks 6 days ago

Conference Call with Viyash Scientific Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 4 months ago